To evaluate the safety and efficacy of plasmakinetic enucleation of the prostate (PKEP) for the treatment of symptomatic benign
prostatic hyperplasia (BPH) compared with 160‑W lithium triboride laser photoselective vaporization of the prostate (PVP). From
February 2011 to July 2012, a prospective nonrandomized study was performed. One‑hundred one patients underwent PKEP, and
110 underwent PVP. No severe intraoperative complications were recorded, and none of the patients in either group required a blood
transfusion. Shorter catheterization time (38.14 ± 23.64 h vs 72.54 ± 28.38 h, P < 0.001) and hospitalization (2.32 ± 1.25 days vs
4.07 ± 1.23 days, P < 0.001) were recorded in the PVP group. At 12‑month postoperatively, the PKEP group had a maintained
and statistically improvement in International Prostate Symptom Score (IPSS) (4.07 ± 2.07 vs 5.00 ± 2.10; P < 0.001), quality of
life (QoL) (1.08 ± 0.72 vs 1.35 ± 0.72; P = 0.007), maximal urinary flow rate (Qmax) (24.75 ± 5.87 ml s−1 vs 22.03 ± 5.04 ml s−1;
P < 0.001), postvoid residual urine volume (PVR) (14.29 ± 6.97 ml vs 17.00 ± 6.11 ml; P = 0.001), and prostate‑specific
antigen (PSA) value (0.78 ± 0.57 ng ml−1 vs 1.27 ± 1.07 ng ml−1; P < 0.001). Both PKEP and PVP relieve low urinary tract
symptoms (LUTS) due to BPH with low complication rates. PKEP can completely remove prostatic adenoma while the total amount
of tissue removed by PVP is less than that can be removed by PKEP. Based on our study of the follow‑up, PKEP provides better
postoperative outcomes than PVP.
Asian Journal of Andrology (2016) 18, 1–5; doi: 10.4103/1008-682X.164199; published online: ???
Keywords: electrosurgery; laser therapy; prostate; prostatic hyperplasia; transurethral resection of prostate

Full Text | PDF |